Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free CREO Stock Alerts

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 13 +0.25 (+1.96%)
As of 12:30 PM Eastern
Compare

CREO vs. TSTL, EKF, SPEC, IUG, and BVC

Should you buy Creo Medical Group stock or one of its competitors? Creo Medical Group's main competitors and comparable companies include Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), Intelligent Ultrasound Group (IUG), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Creo Medical Group compare to Tristel?

Tristel (LON:TSTL) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Creo Medical Group has a net margin of 88.33% compared to Tristel's net margin of 15.88%. Tristel's return on equity of 23.64% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Creo Medical Group 88.33%9.56%-20.09%

In the previous week, Creo Medical Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Tristel. Creo Medical Group's average media sentiment score of 0.75 beat Tristel's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
Tristel Neutral
Creo Medical Group Positive

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.15£6.54M£16.2426.39
Creo Medical Group£6M10.53-£25.04M£1.0013.00

22.5% of Tristel shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 7.0% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tristel has a beta of 0.346, indicating that its share price is 65% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market.

Summary

Tristel beats Creo Medical Group on 7 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.12£4.68M£0.4754.04
Creo Medical Group£6M10.53-£25.04M£1.0013.00

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 40.0% of EKF Diagnostics shares are owned by company insiders. Comparatively, 7.0% of Creo Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Creo Medical Group 88.33%9.56%-20.09%

EKF Diagnostics presently has a consensus price target of GBX 35, suggesting a potential upside of 37.80%. Creo Medical Group has a consensus price target of GBX 40, suggesting a potential upside of 207.69%. Given Creo Medical Group's higher probable upside, analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 2 mentions for EKF Diagnostics and 1 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.75 beat EKF Diagnostics' score of 0.34 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EKF Diagnostics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Creo Medical Group
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

EKF Diagnostics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market.

Summary

EKF Diagnostics and Creo Medical Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Creo Medical Group compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

INSPECS Group presently has a consensus target price of GBX 60, suggesting a potential downside of 34.78%. Creo Medical Group has a consensus target price of GBX 40, suggesting a potential upside of 207.69%. Given Creo Medical Group's higher possible upside, analysts plainly believe Creo Medical Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 7.0% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Creo Medical Group has a net margin of 88.33% compared to INSPECS Group's net margin of -2.67%. Creo Medical Group's return on equity of 9.56% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Creo Medical Group 88.33%9.56%-20.09%

In the previous week, Creo Medical Group had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for INSPECS Group. Creo Medical Group's average media sentiment score of 0.75 beat INSPECS Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
Creo Medical Group Positive

INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market.

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
Creo Medical Group£6M10.53-£25.04M£1.0013.00

Summary

Creo Medical Group beats INSPECS Group on 9 of the 16 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Creo Medical Group (LON:CREO) and Intelligent Ultrasound Group (LON:IUG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Intelligent Ultrasound Group has higher revenue and earnings than Creo Medical Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.53-£25.04M£1.0013.00
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by company insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Intelligent Ultrasound Group's net margin of -23.11%. Creo Medical Group's return on equity of 9.56% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

In the previous week, Creo Medical Group had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Intelligent Ultrasound Group. Creo Medical Group's average media sentiment score of 0.75 beat Intelligent Ultrasound Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
Intelligent Ultrasound Group Neutral

Summary

Creo Medical Group beats Intelligent Ultrasound Group on 7 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, BATM Advanced Communications and BATM Advanced Communications both had 1 articles in the media. Creo Medical Group's average media sentiment score of 0.75 beat BATM Advanced Communications' score of 0.66 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BATM Advanced Communications
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Creo Medical Group
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Creo Medical Group has a net margin of 88.33% compared to BATM Advanced Communications' net margin of -14.90%. Creo Medical Group's return on equity of 9.56% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-14.90% -22.13% 0.58%
Creo Medical Group 88.33%9.56%-20.09%

14.3% of BATM Advanced Communications shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 31.0% of BATM Advanced Communications shares are owned by company insiders. Comparatively, 7.0% of Creo Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BATM Advanced Communications has higher revenue and earnings than Creo Medical Group. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£123.20M0.33-£278.26K-£4.20N/A
Creo Medical Group£6M10.53-£25.04M£1.0013.00

BATM Advanced Communications has a beta of 0.754, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market.

Summary

Creo Medical Group beats BATM Advanced Communications on 8 of the 12 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

Export
MetricCreo Medical GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£63.16M£5.78B£7.28B£2.90B
Dividend YieldN/A1.74%2.54%6.14%
P/E Ratio13.0026.43271.52367.86
Price / Sales10.5369.04631.5083,482.27
Price / Cash2.4333.5178.1327.89
Price / Book0.996.1513.447.17
Net Income-£25.04M£149.51M£3.46B£5.89B
7 Day Performance4.84%1.22%2.24%0.36%
1 Month Performance-5.45%6.92%5.14%3.08%
1 Year Performance-5.45%9.88%27.85%22.79%

Creo Medical Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 13
+2.0%		GBX 40
+207.7%		-9.1%£63.16M£6M13.00279
TSTL
Tristel
N/AGBX 420
+2.4%		N/A+14.3%£201.59M£49.54M25.86208
EKF
EKF Diagnostics
2.6665 of 5 stars		GBX 25.30
flat		GBX 35
+38.3%		-3.5%£108.78M£51.56M53.83356
SPEC
INSPECS Group
0.5654 of 5 stars		GBX 94
-3.1%		GBX 60
-36.2%		+116.1%£102.62M£191.70MN/A1,673
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CREO) was last updated on 8/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel